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eply
e thank Dr. Grundtvig and colleagues for their interest in our
aper (1). They have concerns regarding: 1) the mortality figures;
) achieved drug prescription; and 3) use of diuretics in the
ATTLESCARRED (NT-proBNP-Assisted Treatment To
essen Serial Cardiac Readmissions and Death) trial (1) of
ormone-guided treatment of heart failure.
. They assert incorrect mortality figures, having misread Table 4
(1), which documents composite end points not deaths. One-
year mortality was 18.9% (23 deaths) in the usual care group
and 9.1% (11 deaths) in both intensively followed groups, not
16, 6, and 7 deaths, as asserted by Dr. Grundtvig and
colleagues. Similarly, 3-year mortality in those under 75 years of
age was 15.5% (9 deaths) in the hormone-guided subgroup and
30.9% (17 deaths) and 31.3% (20 deaths) in the other 2 groups,
not 6, 6, and 12 deaths as Grundtvig and colleagues write. The
correct figures are stated in the Results section and are illus-
trated with tabled numbers in Figure 2 (1).
. That the prescription of angiotensin-converting enzyme inhib-
itor/angiotensin receptor blocker, beta-blockade, and spirono-
lactone was somewhat higher in the Norwegian Heart Failure
Registry than in BATTLESCARRED is of interest and may
reflect the younger age of registry subjects (71 years) compared
with trial patients (median age: 75 to 76 years). As stated in the
Methods section (1), the trial design mandated prescription of
drugs to trial-based levels or intolerance in both intensively
followed groups, and this principle was followed scrupulously.
Intolerable side effects (commonly hypotension or azotemia)
were more frequent in those over 75 years of age. Nevertheless,
the proportions of patients receiving evidence-based drugs, and
doses achieved, were similar to those seen in previous trials and
reflect “real-life” limitations on dose escalation in this fragile
group of patients. In addition, our patients all had to have
clearly elevated N-terminal pro–B-type natriuretic peptide lev-
els as an inclusion criterion, which is likely to have selected a
more fragile population (more prone to drug intolerance) than
those in the Norwegian registry.
. We do not claim that our results mandate escalation of diuretic
doses in the presence of persistently elevated N-terminal
pro–B-type natriuretic peptide levels. In fact, final diuretic
doses were similar in both intensively managed groups (Table 3
of our study [1]), although they were more frequently adjusted
(both up and down) in the hormone-guided group. However, it
is clear that patients under 75 years of age were frequently able
to tolerate increased doses of diuretics without hypotension or
azotemia, and in the case of the hormone-guided group, this roccurred together with improved 3-year survival. We make no
claim that higher diuretic dose directly improved mortality. The
fact that diuretic dose is associated with increased mortality in
the Norwegian registry is no surprise given that decompensa-
tion is the prime trigger for increasing doses. However, such an
association in no way indicates that diuretics cannot be appro-
priately and beneficially increased in addition to neurohormonal
blockade provided proper clinical surveillance (to avoid hypo-
tension, azotemia, and other problems) is sustained.
Finally, we agree that any shift in clinical management requires
ood evidence and suggest that this is now accumulating with 4
andomized controlled trials consistently suggesting that at least
ounger (age 75 years) patients with heart failure may benefit
rom consideration of serial B-type peptide levels in monitoring
nd adjusting treatment.
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ractical Considerations
or 1-Day Stress-Only
yocardial Perfusion Protocol
hang et al. (1) explore the advantages of technetium (Tc-99m)
estamibi and Tc-99m tetrafosmin 1-day stress-only perfusion
maging. This is an invaluable protocol in cardiac nuclear stress
esting, especially in light of the growing concern surrounding
adiation exposure secondary to physician-ordered imaging tests
2). Additionally, as the investigators mention, it decreases overall
ost, decreases radiopharmaceutical doses, and takes less time for the
atient in comparison to a study that also requires rest imaging (1).
Chang et al. (1) argue that the 1-day stress/rest Tc-99m
rotocol is preferable, because of the option to forego rest images
hen stress perfusion scans are normal. It is notable, however, that
hen this protocol requires rest images, there is a longer wait time
etween images secondary to higher tracer uptake during the low
tress image when compared with the wait time between images in
1-day rest/stress Tc-99m protocol (3).
Their report (1) states that stress imaging should be followed byest imaging “only in patients with equivocal or clearly abnormal
